From Pregnancy to Preeclampsia: A Key Role for Estrogens

Area of Science:

• Reproductive endocrinology
• Maternal-fetal medicine
• Biochemical analysis

Background:

• Preeclampsia (PE) is a major cause of maternal and fetal mortality, characterized by placental dysfunction.
• Estrogen, primarily produced by the placenta during pregnancy, influences angiogenesis and vasodilation.
• Previous studies on estrogen synthesis in PE yielded conflicting results due to assay limitations.

Purpose of the Study:

• To review current knowledge on estrogen synthesis, regulation, and effects in pregnancy and PE.
• To explore the relationship between PE, estrogen biosynthesis, angiogenic factors, and cardiovascular risk.
• To highlight the potential of estrogen levels as a biomarker for PE.

Main Methods:

• Review of recent scientific literature on estrogen metabolism and preeclampsia.
• Analysis of studies employing advanced analytical techniques like liquid chromatography/mass spectrometry and gas chromatography/mass spectrometry.
• Synthesis of data linking estrogen dysregulation to PE pathophysiology.

Main Results:

• Recent studies using reliable assays suggest significantly decreased estradiol levels in preeclampsia.
• Estrogen dysregulation is closely linked to the occurrence of PE.
• Evidence points to a connection between estrogen, angiogenic factors, and cardiovascular risk in PE.

Conclusions:

• Estrogen dysregulation is implicated in preeclampsia pathogenesis.
• Estrogen levels may serve as a valuable biomarker for preeclampsia.
• Targeting estrogen pathways could offer novel prevention or treatment strategies for PE.